Invited Speakers
Irena Adkins
VRG Therapeutics, Budapest, Hungary
Drug Development: From Target Validation to First-in-Human Studies
Roberto F. Alvarez
i&I Prague, Czech Republic
Technology transfer system of IOCB – how to build a start-up
Stephan Bachmann
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Scale-Up of Organometallic Flow Chemistry - A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib
Haim Barr
Weizmann Institute of Science, Rehovot, Israel
The role of diversified platforms in academic drug discovery
Miklos Bekes
Arvinas Inc., New Haven, Connecticut, United States
PROTAC targeted protein degraders – the future is now
Filip Doušek
Theorema AI, Czech Republic
Causal disease modelling
Zdeněk Hostomský
IOCB Prague, Czech Republic
Development of PARP inhibitors - A case study
Shea Johnson
AbbVie, Ludwigshafen, Germany
TBD
Gabriela Koifman
Weizmann Institute of Science, Rehovot, Israel
Gene Amplification Evolution as a Mechanism of Cancer Adaptation and Drug Resistance in Patient-Derived Organoids
Valery Krizhanovsky
Weizmann Institute of Science, Rehovot, Israel
Senescent cells: where to find them and how to deal with them
Donna Matzov
Weizmann Institute of Science, Rehovot, Israel
Single-Particle Cryo-EM in GPCR Drug Discovery: Methodology and Case Studies
Chris Meier
University of Hamburg, Department of Chemistry
Institute of Organic Chemistry, Germany
Enzyme- or photocleavable masking for the intracellular delivery of bioactive highly phosphorylated nucleotides
Luke Piggott
Debiopharm, Lausanne, Switzerland
TBD
Katarína Pšenáková
PharmTheon, Czech Republic
Beyond the Bench - Building Therapies That Matter
Neta Regev-Rudzki
Weizmann Institute of Science, Rehovot, Israel
Cell-communication in malaria: the parasite’s social media network
Menachem Rubinstein
Weizmann Institute of Science, Rehovot, Israel
Bispecific VSV-G Engagers: A Platform for Targeted in vivo Gene Delivery
David Stíbal
i&I Prague, Czech Republic
Technology transfer system of IOCB – how to build a start-up
Yosef Yarden
Weizmann Institute of Science, Rehovot, Israel
Mechanisms of resistance to anti-cancer kinase inhibitors
Eliane Hadas Yardeni
Weizmann Institute of Science, Rehovot, Israel
GPCRs through the Ligand Lens: Exploring Dopamine Receptor Pharmacology
